Genome editing with targeted nucleases and DNA donor templates homologous to the break site has proven challenging in human hematopoietic stem and progenitor cells (HSPCs), and particularly in the most primitive, long-term repopulating cell population. Here we report that combining electroporation of zinc finger nuclease (ZFN) mRNA with donor template delivery by adeno-associated virus (AAV) serotype 6 vectors directs efficient genome editing in HSPCs, achieving site-specific insertion of a GFP cassette at the CCR5 and AAVS1 loci in mobilized peripheral blood CD34 + HSPCs at mean frequencies of 17% and 26%, respectively, and in fetal liver HSPCs at 19% and 43%, respectively. Notably, this approach modified the CD34 + CD133 + CD90 + cell population, a minor component of CD34 + cells that contains long-term repopulating hematopoietic stem cells (HSCs). Genome-edited HSPCs also engrafted in immune-deficient mice long-term, confirming that HSCs are targeted by this approach. Our results provide a strategy for more robust application of genome-editing technologies in HSPCs.
A r t i c l e s
Gene therapy using HSPCs is increasingly being applied to treat severe genetic diseases [1] [2] [3] [4] . A patient's own HSPCs can be genetically modified following a short ex vivo culture in the presence of hematopoietic cytokines, and integrating viral vectors such as lentiviral vectors are often used to confer long-lasting effects. However the semi-random nature of vector insertion can result in nonauthentic patterns of gene expression, including silencing over time, or harmful insertional mutagenesis events, such as transactivation of neighboring oncogenes [5] [6] [7] . In contrast, genome editing with targeted nucleases-which include ZFNs, transcription activator-like effector nucleases, and the clustered, regularly interspaced, short palindromic repeats-associated protein 9 endonuclease-enables gene disruption, correction of a gene mutation or insertion of new DNA sequences in a highly regulated manner at preselected target sites. These nucleases act by catalyzing sitespecific DNA double-strand breaks (DSBs) 8 . Repair of DSBs can proceed by nonhomologous end joining (NHEJ) or homologydirected repair (HDR) [9] [10] [11] [12] , and these pathways are exploited to achieve the desired form of genetic modification 13 . The therapeutic applications of genome editing that are closest to clinical translation are disruption of the HIV-1 coreceptor CCR5 to treat HIV 14 and of the γ-globin repressor BCL11A 15 as a therapy for β-globinopathies. Both of these programs involve gene knockout, whereas the ability to correct mutations or add DNA sequences would substantially broaden the impact of gene editing technologies.
HDR-mediated genome editing requires the introduction into a cell of both a targeted nuclease and a matched homologous donor DNA repair template. As both components have to be present only transiently to permanently modify a genome, it is possible to deliver them using nonpermanent delivery vehicles, including nucleic acids (plasmid DNA, mRNA and oligonucleotides) and certain viral vectors (integrase-defective lentivirus (IDLV), adenovirus, and AAV). Application of these methods is now quite straightforward for cell lines and a variety of primary cells [16] [17] [18] [19] , but their use in HSPCs is particularly challenging, especially for insertion of a full transgene expression cassette. Initial attempts at editing human CD34 + HSPCs with IDLVs only achieved efficiencies below 0.1% (ref. 20) . More recently, combining the introduction of ZFNs as mRNA with IDLV donor templates resulted in the site-specific insertion of GFP cassettes in ~5% of HSPCs, with a further twofold increase possible when the cells were incubated in the presence of dmPGE2 and SR1 (ref. 21 ). However, analysis of editing rates in the most primitive HSPCs, identified by expression of CD90 (refs. 22,23) or by studies involving transplantation of cells into immune-deficient mice, have highlighted the difficulty of editing the most primitive, long-term repopulating HSCs compared to the more differentiated subsets that are also present in the bulk CD34 + HSPC population 21, 24 .
In the present study we evaluated the potential of AAV vectors to function as homologous donor templates. By identifying AAV6 as a capsid variant with high tropism for human HSPCs, and combining this method of donor delivery with mRNA delivery of ZFNs, we demonstrated dose-dependent site-specific insertion of small or large gene cassettes at two different endogenous loci. The high levels of genome editing observed in bulk CD34 + HSPC populations were Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mrNA and AAV6 donors
RESULTS

Human HSPCs are efficiently transduced by AAV6 vectors
We first compared the ability of different AAV serotypes to transduce HSPCs. We used AAV vectors expressing GFP reporter genes, and packaged into capsids from serotypes 1, 2, 5, 6, 8 and 9. These were evaluated at a range of doses on CD34 + HSPCs isolated from either mobilized peripheral blood or fetal liver.
For both types of HSPC, AAV6 gave the highest rates of transduction across a range of vector doses (Fig. 1) . The next most-efficient serotype was the closely related variant, AAV1. This agrees with prior reports describing the tropism of AAV6 vectors for human HSPCs [25] [26] [27] .
HDR-mediated editing in HSPCs by ZFN mRNA and AAV6 donors We examined the ability of AAV6 vectors to deliver a homologous donor template to mobilized blood CD34 + HSPCs and thereby direct HDR-mediated genome editing in cells also treated with a targeted nuclease (Fig. 2a) . We transduced the cells with varying doses of AAV6 vectors, followed by electroporation 16-24 h later with mRNA expressing a previously characterized CCR5 ZFN pair 28 . Two different homologous donor templates were evaluated as AAV6 vectors, representing both base pair-specific gene editing events (exemplified by the insertion of a restriction site) and insertion of a larger GFP expression cassette. In each case, the AAV6 vectors contained identical homologous CCR5 sequences flanking either an XhoI restriction site (donor CCR5-RFLP) or a PGK-GFP expression cassette (donor CCR5-GFP) (Fig. 2b) . As these cassettes contain additional sequences between the ZFN binding sites, neither the donor template themselves nor a successfully edited target site would be subject to recutting by the CCR5 ZFNs 24, 29, 30 . The rates of genome editing events were monitored by population deep sequencing and restriction fragment length polymorphism (RFLP) analysis to detect the XhoI insertion, or by flow cytometry and semiquantitative PCR for site-specific GFP addition.
NHEJ and HDR repair are competitive events, and the products of both repair pathways were detected in the treated cell populations by deep sequencing (Fig. 2c and Supplementary Table 1) . Increasing the dose of the CCR5-RFLP vector led to an increase in the rate of XhoI insertion at the CCR5 locus, resulting in >20% of alleles being modified (Fig. 2c) . This was accompanied by a corresponding decrease in the frequency of the indels characteristic of NHEJ-mediated repair, whereas at the highest AAV6 donor levels, cytotoxicity led to a decrease in both types of genome editing events (Fig. 2c,d) . Similarly, increasing levels of stable GFP expression were observed following transduction of the cells with increasing doses of the CCR5-GFP vector, but only in the presence of the CCR5 ZFN mRNA (Fig. 2e-g ).
The optimal time for AAV6 transduction relative to ZFN mRNA electroporation was evaluated and found to be between 24 h pre-and 1 h post-electroporation, indicating that this sequential treatment schedule is relatively flexible (Supplementary Fig. 1 ). The amount of HDR editing at the CCR5 locus achieved under specific conditions also varied between different CD34 + donors (Supplementary Fig. 2 ). For example, using AAV6 vector doses of 3,000 vector genomes (vg)/cell), we achieved a mean rate of RFLP insertion in CCR5 of 15.8% (range 8.4-29.2, n = 15 experiments), whereas a dose of 10,000 vg/cell resulted in a mean rate of 20.1% (range 11.4-32.5, n = 11). These levels of HDR-mediated genome editing were also independent of the HSPC cell source because treatment of fetal liver-derived CD34 + cells with the CCR5-GFP vector and CCR5 ZFN mRNA produced similar high levels of stable and site-specific GFP addition (Supplementary Fig. 3) .
Programmable site-specific nucleases, including ZFNs, can introduce off-target DNA breaks at sequences with homology to the intended target site 31 , although engineering strategies can minimize such effects [32] [33] [34] . In the absence of extensive homology between an off-target break site and a donor sequence, as is often the case, the most frequent genome editing outcome is NHEJ-mediated repair, which can lead to indels 28, 35 . The off-target profile of the CCR5 ZFNs used in this study has been previously described 28, 35, 36 , and deep sequencing of the top 23 known off-target sites in cells treated with the combination of CCR5 ZFNs and the CCR5-GFP donor gave the expected profile (Supplementary Table 2 ).
To establish the generality of these results, we performed an analogous set of studies using reagents specific for the AAVS1 'safe harbor' locus 37, 38 . In mobilized blood HSPCs, insertion of a HindIII restriction site occurred, on average, at 28% of the AAVS1 alleles, whereas GFP addition was observed in >30% of the cells (Supplementary Fig. 4 ). Similar high rates of gene editing at AAVS1 were achieved in fetal liver HSPCs, with stable GFP addition detected in >40% of the cells, without any toxicity (Supplementary Fig. 5 ). Taken together, these results demonstrate that AAV6 vectors are an effective vehicle for delivering homologous donor DNA templates to CD34 + HSPCs, and that when combined with ZFN mRNA electroporation, the protocol supports both base pair-specific genome editing events and larger gene additions at frequencies in the range of 15-40%.
AAV6 vectors use HDR pathways to genetically modify HSPCs
In addition to engaging the cell's HDR pathways to achieve precise on-target genome editing, AAV genomes can also become inserted at the site of a DSB through NHEJ-mediated end-capture events [39] [40] [41] . 
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Such events represent on-target gene additions when occurring at the intended nuclease target site, but are considered off-target when occurring at DSBs generated by either random cellular events or any off-target activity of the nuclease itself ( Supplementary Fig. 6a ).
To further investigate which mechanism was responsible for the high levels of stable GFP expression observed following the introduction of ZFNs and AAV6 donors into cells, we combined CCR5 ZFN mRNA treatment of HSPCs with AAV6 vectors containing GFP expression cassettes but lacking sequences with homology to CCR5. These included a GFP vector with no flanking genomic regions, and one with mismatched arms that were instead homologous to the AAVS1 locus ( Fig. 3a) . As before, the vectors were introduced into the cells and followed 1 day later by CCR5 ZFN mRNA electroporation. Using fetal liver-derived HSPCs, we observed that all three vectors produced similar initial frequencies of GFP + cells at 1 day post-electroporation. This reflected expression of GFP from the episomal AAV vectors, and confirmed equivalent rates of introduction of each of the AAV vectors into HSPCs. However, by day 10, only the cells receiving the AAV6 vector with CCR5 homology arms retained >1% GFP expression (Fig. 3b,c) . In addition, the fluorescence intensity of GFP expression in these cells was considerably less variable than in any of the day 1 populations, as would be expected if gene expression was occurring subsequent to a mostly site-specific integration event. Low levels of GFP + cells were also apparent in the day 10 cultures of cells receiving CCR5 ZFNs and vectors without CCR5 homologous arms. Such expression likely resulted from residual episomal AAV genomes and following endcapture of the AAV genomes into DSBs, including those generated at the CCR5 locus by the ZFNs. Finally, a semiquantitative site-specific PCR assay confirmed that GFP expression in the CCR5-GFP plus CCR5 ZFN day-10 population resulted from insertion of the GFP cassette at the CCR5 locus, and that this HDR-dependent event occurred only when flanking CCR5 sequences were included in the AAV6 vector genome (Fig. 3d) .
Similar results were obtained with mobilized blood CD34 + HSPCs. Here, stable GFP expression after 8 days of culture was observed only when matched combinations of ZFNs and AAV6 donors where used, capable of inserting GFP expression cassettes at either the CCR5 or AAVS1 loci (Fig. 3e,f) . Although low but statistically significant levels (P < 0.05) of GFP + cells were observed when the mismatched combinations of AAV6 donors and ZFNs were used, presumably due to endcapture of AAV genomes at the ZFN-generated DSBs, these occurred at only ~4% of the rate that on-target HDR-mediated events occurred at each locus when matched reagents were used ( Supplementary  Fig. 6b,c) . It is also likely that such events would occur at even lower frequencies when the matched combinations of reagents were used, as they would also be in competition with HDR-mediated pathways.
In summary, the requirement for matched homologous sequences to support the highest levels of gene addition at the CCR5 and AAVS1 loci identifies HDR pathways as the predominant mechanism leading to stable genome editing in HSPCs.
Analysis of HSPCs treated with AAV6 and ZFN mRNA
We examined the ability of mobilized blood HSPCs treated with the CCR5-RFLP vector plus CCR5 ZFN mRNA to proliferate in culture, to differentiate into hematopoietic lineages and to maintain consistent levels of genome-edited cells in the population. When the cells were grown in bulk culture, we observed an initial decrease of 23% in the absolute number of cells present in the population treated with both vector and ZFNs at 1 day post-electroporation, compared to the other arms of the experiment. However, by 2 days post-electroporation, the rate of growth of these cells had become indistinguishable from a mock-treated population (Fig. 4a) . In addition, the frequency of genome-edited events in the population did not vary over 9 days of culturing, with the frequency of site-specific RFLP insertions being 19.56% at day 2 and 19.45% at day 9. Together, these data indicate that although some of the cells in the bulk CD34 + population were sensitive to the AAV6 plus ZFN treatment, the proliferative potential of the surviving cells was not affected, suggesting that any such effects could be compensated for by using higher initial numbers of cells.
We also plated AAV6 and ZFN-treated cells in methylcellulose and analyzed the colonies that formed. Here, we found no difference in the relative percentages of the different colony subtypes that developed in the various treatment arms of the experiment (Fig. 4b) . In addition, by picking colonies from the methylcellulose cultures and analyzing their genotype, we confirmed that the levels of genome editing in the myeloid colonies (colony-forming unit granulocyte/macrophage/ granulocyte and macrophage; CFU-G/M/GM) and erythroid colonies (colony-forming unit erythroid and burst-forming unit erythroid; CFU/BFU-E) were indistinguishable from the levels in the bulk liquid 
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A r t i c l e s culture (Fig. 4c) . The numbers of CFU granulocyte/erythroid/macrophage/megakaryocyte (GEMM) colonies obtained for all conditions were too low to quantitate. Finally, in a similar experiment using the CCR5-GFP vector, we observed GFP + cells in all colony types (Fig. 4d) . Taken together, these data indicate that the combined AAV6 transduction/ZFN mRNA treatment does not adversely affect the growth or differentiation potential of HSPCs.
Efficient genome editing in primitive subsets of CD34 + HSPCs CD34 + cells comprise a mixed population of primitive and more differentiated cells that can be further distinguished based on the expression of additional markers 23 . The CD90 + subset in particular has been associated with long-term repopulating activity 22, 42, 43 , and CD34 + CD90 + cells can provide long-term multilineage engraftment in patients undergoing cancer treatment 44, 45 . However, the most primitive cells, including those defined as CD34 + CD133 + CD90 + , or capable of persisting in transplanted immune-deficient mice, have proven to be the most difficult to edit when ZFNs have been combined with donor templates delivered by IDLVs 21, 24 .
To evaluate the ability of AAV6 donors to promote HDR-mediated gene editing in primitive cells, we treated bulk CD34 + populations isolated from fetal liver with CCR5-GFP AAV6 vectors and CCR5 ZFN mRNA and then sorted them into different subsets. We defined subsets within the bulk (B) CD34 + population as primitive (P), early (E) and committed (C) progenitors, based on expression of CD133 and CD90 (refs. 21,23) (Fig. 5a) . We cultured each population for a further 7 days, then measured the levels of stable GFP expression in the different populations by flow cytometry. We readily detected stable GFP expression in each of the subsets, with no statistically significant difference in the levels in the most primitive cells compared to either the bulk unsorted CD34 + population or other sorted subsets (Fig. 5b,c) . These observations were further validated by performing site-specific In-Out PCR to confirm insertion of GFP at the CCR5 locus (Fig. 5d) .
Cultured fetal liver HSPCs are quite proliferative, which may increase their permissiveness to HDR-mediated repair. We therefore repeated these experiments using the more clinically relevant mobilized blood CD34 + HSPCs, and using reagents targeting both the CCR5 and AAVS1 loci. These analyses also demonstrated equivalent levels of HDR-mediated gene addition in the CD34 + CD133 + CD90 + population as in the bulk CD34 + population or the more differentiated progenitors (Fig. 5e-h) . Taken together, these data suggest that the combination of ZFN mRNA electroporation and AAV6 donor ,000 vg/cell CCR5-GFP and 60 µg/ml CCR5 ZFN mRNA at day 8. The gating strategy used to isolate the P, E and C populations from the bulk CD34 + population is shown in Supplementary Figure 12a. (f) Mobilized blood CD34 + HSPCs were treated as in e, but using 10,000 vg/cell AAVS1-GFP and AAVS1 mRNA. (g) In-Out PCR to detect GFP insertion at the CCR5 locus in the indicated subsets and treatments. Numbers for values above background controls are shown. (h) In-Out PCR to detect GFP insertion at the AAVS1 locus in the indicated subsets and treatments. Numbers for values above background controls are shown. Uncropped images of all gels in this figure are available in Supplementary Figure 12. template delivery provides the capability of editing even the most primitive compartment of CD34 + HSPCs.
Genome-edited HSPCs engraft and differentiate in NSG mice
The long-term engraftment potential of human HSCs can be evaluated by their ability to engraft and differentiate in immune-deficient mice. Such severe combined immunodeficient (SCID)-repopulating cells are considered surrogates for long-term repopulating HSCs 46 . In mouse HSC studies, long-term-repopulating HSCs are also defined by their ability to further persist during secondary transplantations 23, [47] [48] [49] [50] . However, as it is especially difficult to demonstrate secondary transplantations when using mobilized blood CD34 + cells 51 , we first used fetal liver-derived cells for these analyses.
Fetal liver CD34 + cells were transduced with CCR5-GFP or CCR5-RFLP vectors followed by electroporation with CCR5 ZFN mRNA, then engrafted into neonatal nonobese diabetic (NOD)-SCID-gamma (NSG) mice and monitored over 16 weeks. Analysis of peripheral blood at weeks 8, 12 and 16 post-transplantation, and the bone marrow and spleen at 16 weeks, revealed robust development of human CD45 + leucocytes at levels that were indistinguishable from mice receiving untreated control HSPCs (Fig. 6a) . At each time point, the human cells were further stained for lineage-specific markers and analyzed for the presence of B cells (CD19 + ), monocytes (CD3 − CD4 + ), CD4 T cells (CD3 + CD4 + ) and CD8 T cells (CD3 + CD4 − ) (Supplementary Fig. 7 ). This revealed that the treated HSPCs were capable of differentiating into each lineage at rates similar to those of untreated cells, confirming no difference in hematopoietic potential for the treated cells, and agreeing with the observations from the in vitro CFU analyses (Fig. 4) .
We also examined the levels of genome editing in the human cells that developed in the mice over time. Using flow cytometry for cells from the CCR5-GFP mice or deep sequencing for the CCR5-RFLP mice, we readily observed edited cells in both the circulation and tissues. This was detected in both the bulk human CD45 + cell populations (Fig. 6b) , as well as in individually sorted lineages (Supplementary Fig. 8) . Evidence of site-specific GFP insertion at the CCR5 locus was also confirmed in the blood and tissues of individual mice from the CCR5-GFP plus ZFN cohort by In-Out PCR (Fig. 6c) .
Together, these results demonstrate that modified human HSPCs are capable of engrafting mice and differentiating into multiple different lineages that retain the genomic edits.
Finally, we evaluated the ability of the genome-edited human HSPCs to persist during secondary transplantations 47 . Bone marrow was harvested from two mice from each of the separate CCR5-GFP or CCR5-RFLP cohorts and was pooled and used to transplant one additional adult NSG mouse for each group. The bone marrow of these secondary transplant recipients was then analyzed 20 weeks later, revealing that these cells had frequencies of genome editing that were at similar or higher levels when compared to the input primary bone marrow samples (Fig. 6d) . As these cells had persisted for a total of 36 weeks in the mice and survived during secondary transplantation, the data support the conclusion that long-term SCID-repopulating cells in the initial population of treated CD34 + cells had been modified.
We also evaluated the extent of genome editing that could be detected in the human cells that persisted long-term (20 weeks) in NSG mice transplanted with mobilized blood HSPCs (Fig. 6e) . These cells do not transplant in NSG mice as robustly as fetal liver HSPCs, and the graft declines over time 23, 36, 51, 52 (Supplementary Fig. 9) , making it more difficult to obtain molecular data from human cells at later time points. NSG mice were engrafted with mobilized blood HSPCs that had been treated with AAVS1-GFP vectors, in the presence or absence of the matched AAVS1 ZFNs, and maintained for 20 weeks. Using an In-Out PCR assay, we were able to demonstrate site-specific GFP insertion at the AAVS1 locus in bone marrow from 6/10 of the mice receiving both the AAV6 vectors and ZFNs, whereas none of the three mice receiving just the AAV6 vectors were positive in the same assay (Fig. 6f) . The observation of long-term persistence of the GFP cassette at the targeted AAVS1 locus is also consistent 
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with an ability to edit the most primitive cells in the mobilized blood CD34 + cell population.
DISCUSSION
Precision genome engineering through the use of targeted nucleases is likely to be especially important when the cellular target is a long-lived cell such as an HSC. Achieving HDR-mediated gene editing at efficient levels requires optimization of several steps. First, the targeted nuclease must be introduced into the cell at sufficiently high levels and without toxicity. Next, a homologous donor template must also be introduced. This template can be single-stranded or double-stranded DNA, and presented as a viral vector, bacterial plasmid or synthesized oligonucleotide 20, 29, 30 , although the size limitations of oligonucleotides makes them more suited for gene correction purposes than transgene addition. A major limitation here for HSPCs can be cytotoxicity, and we have found that plasmid DNA and adenoviral vectors are less well tolerated in HSPCs than in transformed cells 36 . Finally the template must engage the HDR machinery, which is most active in the S/G2 phase of the cell cycle 53 . In the case of CD34 + HSPCs, a further requirement for many applications is that all of these events occur in the most primitive long-term repopulating stem cells, which represent only a minority of the CD34 + population 54 .
We found mRNA electroporation to be a highly effective method to deliver ZFNs 21, 30 as it resulted in high levels of DNA cleavage at the targeted CCR5 or AAVS1 loci without overt cytotoxicity. We further found that mRNA delivery of ZFNs could be effectively combined with donor template delivery by AAV vectors to achieve HDR-mediated genome editing, with a certain amount of flexibility in the sequence and timing of the two events. A potentially rate-limiting step of transduction of HSPCs by the AAV vectors was overcome by using the HSPC-tropic serotype AAV6. The combination of ZFN mRNA and AAV6 vectors allowed site-specific insertion of a promoter-GFP cassette at the CCR5 and AAVS1 loci at mean frequencies of 17% and 26%, respectively, in mobilized blood HSPCs, and at 19% and 43%, in fetal liver HSPCs.
AAV vectors, in the absence of nuclease, have previously been used to promote HDR [55] [56] [57] , and have found application in transgenics 58 . The AAV genome exists in single-stranded and double-stranded forms, both of which could potentially serve as substrates for HDR, and it has been suggested that AAV inverted terminal repeats may be particularly recombinogenic 59, 60 . The capsid packaging limitation of 4.7 kb can easily accommodate the homology arms necessary to introduce a small gene correction. Furthermore, for gene insertion applications, the specific homology arms we used to target the AAVS1 locus could allow an additional gene cassette of ~3.0 kb. AAV vectors also have the advantage that they are relatively easily manufactured at high titers for clinical applications.
An important consideration when working with CD34 + HSPCs is the ability to modify the most primitive cells in the population, which contribute to ongoing multilineage hematopoiesis 44, 45 . Previous work using IDLV donors has shown that although rates of HDR in the bulk CD34 + population reach ~12% (GFP + cells) when used in combination with dmPGE2 and SR1 stimulation, the vectors support much lower levels of editing in long-term-repopulating HSCs, as seen in both in vitro cultures and humanized mice experiments 21, 24 . In contrast, we found that donor templates provided as AAV6 vectors were able to direct high levels of genome editing in even the primitive CD34 + CD133 + CD90 + subset of cells in vitro without additional manipulation and at rates that were indistinguishable from those of the bulk CD34 + population. In addition, the treated HSPCs supported long-term multilineage engraftment of humanized mice, including secondary transplantations, consistent with modification of long-term-repopulating HSCs. Furthermore, our data suggest that there is not an inherent defect in the HDR machinery in longterm-repopulating HSCs, at least when the cells are cultured ex vivo for short periods of time.
In summary, we have demonstrated that homologous donor template delivery by AAV6 vectors can be combined with ZFN mRNA electroporation to achieve high levels of precise genome editing in human HSPCs, including in the most primitive population. As HDR acts downstream of DSB formation, it is likely that AAV6 vectors will have similar utility as partners for all classes of targeted nucleases for this cell population. In this way they provide a means of broadening the application of genome engineering for the treatment of human diseases of the blood and immune systems.
METHODS
Methods and any associated references are available in the online version of the paper. 
